文献速递神经核医学

[18F]氟比他班PET在记忆门诊诊断不明确患者中的临床影响

Clinical impact of [18F]flutemetamol PET among memory clinic patients with an unclear diagnosis.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-03-26

该研究纳入207例经全面认知评估后诊断仍不明确的记忆门诊患者,行[18F]氟比他班淀粉样蛋白PET后,44%(92/207)的患者诊断发生改变,胆碱酯酶抑制剂治疗显著增加(+218%,从34例增至108例),支持淀粉样蛋白PET在诊断不确定患者中的临床价值。

要点

  • 淀粉样蛋白PET使44%(92/207)诊断不明确患者的诊断发生改变。
  • MCI组诊断改变比例最高(51%,67例),痴呆NOS组为55%(11例)。
  • PET后胆碱酯酶抑制剂治疗增加218%(34例增至108例)。

核心结论

  • 淀粉样蛋白PET对三级记忆门诊中诊断不明确患者具有临床价值,可改变诊断并影响治疗管理。

研究设计与样本

  • 研究纳入207例三级记忆门诊患者,均在行[18F]氟比他班PET前经神经心理测试、结构影像、脑脊液生物标志物及部分[18F]FDG PET评估后诊断仍不明确。
  • PET前临床诊断包括MCI 131例、AD 41例、非AD 10例、痴呆NOS 20例和SCD 5例。

主要发现

  • 淀粉样蛋白阳性率:MCI 53%、AD 68%、非AD 20%、痴呆NOS 20%、SCD 60%。
  • [18F]氟比他班PET使207例中92例(44%)诊断发生改变。
  • 诊断改变比例:MCI组51%(67例)、痴呆NOS组55%(11例)、非AD组30%、AD组20%。
  • PET后胆碱酯酶抑制剂治疗增加218%(34例增至108例)。

临床怎么用

  • 对经全面评估仍诊断不明确的记忆门诊患者,可考虑行淀粉样蛋白PET以辅助诊断分型。
  • 淀粉样蛋白PET结果可支持胆碱酯酶抑制剂治疗的启动或调整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the impact of amyloid PET with [18F]flutemetamol on diagnosis and treatment management in a cohort of patients attending a tertiary memory clinic in whom, despite extensive cognitive assessment including neuropsychological testing, structural imaging, CSF biomarker analysis and in some cases [18F]FDG PET, the diagnosis remained unclear. METHODS: The study population consisted of 207 patients with a clinical diagnosis prior to [18F]flutemetamol PET including mild cognitive impairment (MCI; n = 131), Alzheimer's disease (AD; n = 41), non-AD (n = 10), dementia not otherwise specified (dementia NOS; n = 20) and subjective cognitive decline (SCD; n = 5). RESULTS: Amyloid positivity was found in 53% of MCI, 68% of AD, 20% of non-AD, 20% of dementia NOS, and 60% of SCD patients. [18F]Flutemetamol PET led, overall, to a change in diagnosis in 92 of the 207 patients (44%). A high percentage of patients with a change in diagnosis was observed in the MCI group (n = 67, 51%) and in the dementia NOS group (n = 11; 55%), followed by the non-AD and AD (30% and 20%, respectively). A significant increase in cholinesterase inhibitor treatment was observed after [18F]flutemetamol PET (+218%, 34 patients before and 108 patients after). CONCLUSION: The present study lends support to the clinical value of amyloid PET in patients with an uncertain diagnosis in the tertiary memory clinic setting.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Leuzy A, Savitcheva I, Chiotis K, et al. Clinical impact of [18F]flutemetamol PET among memory clinic patients with an unclear diagnosis. Eur J Nucl Med Mol Imaging. 2019. PMID: 30915522. doi:10.1007/s00259-019-04297-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。